AstraZeneca drops breast, prostate cancer programs in Q4 pipeline cull Pipeline Therapeutics banks $80M to propel hearing loss, MS programs Flagship names Miralles as latest CEO-partner Sponsored: Understanding the pharmaceutical lifecycle and the benefits of a menu-driven approach After nabbing new CEO, Penrose TherapeuTx hires Pfizer, Astellas veteran chief development officer Ensoma debuts with $70M, Takeda deal to pursue off-the-shelf genomic medicines Biotech entrepreneur George Church launches gene therapy startup to design safer viral vectors PacBio nets $900M from SoftBank to support its long-read sequencing goals Featured Story | By Nick Paul Taylor AstraZeneca has dropped two oncology programs from its clinical-phase pipeline. The Big Pharma has stopped work on AZD9496 in breast cancer and imaradenant in prostate cancer on safety or efficacy grounds. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Nearly three years after launch, Versant spinout Pipeline Therapeutics is banking $80 million to push its lead neurodegenerative disease programs through the clinic. The funds will bankroll clinical trials for programs in hearing loss and multiple sclerosis while supporting the company’s earlier-stage work. read more By Nick Paul Taylor Diego Miralles has joined Flagship Pioneering as CEO-partner. Flagship disclosed the appointment of Miralles, who will serve as CEO of its portfolio company Laronde, alongside news that it has hired ex-Rubius Therapeutics executive Andrew Oh as senior partner. read more Sponsored By: Avid Bioservices The concept of one-stop shopping has become more popular in the biopharmaceutical industry in recent years, prompting many traditional commercial manufacturing organizations (CMOs) to provide support to clients throughout the manufacturing lifecycle. read more By Ben Adams Cancer biotech startup Penrose TherapeuTx is continuing its C-suite change-up by hiring oncology specialist Bhardwaj Desai, M.D., as its new chief development officer. read more By Amirah Al Idrus From therapies that replace disease-causing genes with normal ones to CRISPR-based treatments that edit genes inside the body, the biotech industry has made tremendous strides in genomic medicine. Despite these advances, today’s approaches still have requirements that limit their accessibility. Ensoma hopes to change that with a suite of off-the-shelf genomic medicines. read more By Angus Liu The adeno-associated viruses often used as vectors to deliver gene therapy can trigger unwanted and sometimes dangerous immune responses. Now, a Harvard University team led by renowned geneticist George Church, Ph.D., has developed a way to "cloak" AAVs from immune surveillance. They've spun off Ally Therapeutics to develop it. read more By Conor Hale Just over a year after Illumina’s $1.2 billion bid for its fellow sequencer manufacturer fell apart under federal scrutiny, Pacific Biosciences has secured a new benefactor with a $900 million commitment from SoftBank. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
|---|
|
Resources Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Learn what it takes to get a drug developed and approved February 23-24, 2021 | 12 p.m. EST / 9 a.m. PST For non-scientists. Learn the science driving biopharma. February 25-26, 2021 | 9 a.m. EST / 6 a.m. PST Learn what it takes to get a drug developed and approved March 9-10, 2021 | 9 a.m. EST / 6 a.m. PST Learn the science driving biopharma. Specific for the non-scientist. March 18-19, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Learn what it takes to get a drug developed and approved April 22-23, 2021 | 9:00 a.m. EST / 6 a.m. PST Learn the science driving biopharma. Specific for the non-scientist. May 6-7, 2021 | 9:00 a.m. EST / 6 a.m. PST Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved June 2-3, 2021 | 9 a.m EST / 6 a.m.PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. | 